Objectives The additional impact of coexisting Sjögren’s syndrome (SS) on cardiac involvement in patients with systemic lupus ...
Objective Fatigue is a common, multifaceted symptom in SLE which is difficult to treat. There has been a lack of broadly ...
Objective We aimed to characterise differences in the occurrence of maternal cardiovascular events (CVEs) and adverse ...
Moreover, as some clinical trials have excluded them, the efficacy of some immunosuppressants for this subset of patients has not been strictly confirmed. In this study, we aimed to investigate the ...
Background SLE features aberrant type I interferon production, with the stimulator of interferon genes (STING) pathway acting as a key upstream driver. However, its expression patterns in patients ...
The association between SLE and composite stroke, ischaemic stroke and haemorrhagic stroke remains incompletely understood. This meta-analysis aims to assess the risk of stroke in patients with ...
Background Global collaboration is a key driver of advances in complex diseases such as lupus, yet its distribution and ...
Background Systemic lupus erythematosus (SLE) is a chronic autoimmune disease influenced by multiple factors. Growing evidence suggests that adverse childhood experiences (ACEs) and post-traumatic ...
The case for early biologic therapy in systemic lupus erythematosus (SLE) is intuitively appealing but requires closer scrutiny. First, ‘early’ is poorly defined with UK survey data showing a mean ...
Systemic lupus erythematosus (SLE) is a profoundly heterogeneous disease in which clinical phenotype emerges from the interplay of autoantibody profiles, organ involvement, cytokine signatures, ...
Objective Lupus nephritis (LN) is a potentially severe manifestation of SLE, often resulting in permanent kidney damage. We investigated whether polygenic and/or epigenetic risk is associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results